=Alkermes (ALKS) reported earnings on Thur 27 April 2017 (b/o)

Alkermes misses by $0.09, misses on revs :

• Reports Q1 (Mar) loss of $0.18 per share, $0.09 worse than the Capital IQ Consensus of ($0.09); revenues rose 22.3% year/year to $191.8 mln vs the $195.79 mln Capital IQ Consensus.
  • Net sales of VIVITROL were $58.5 million, compared to $43.8 million for the same period in the prior year, representing an increase of approximately 33.4%.
  • Net sales of ARISTADA were $18.0 million, compared to $5.5 million for the same period in the prior year.
  • Manufacturing and royalty revenues from RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA were $60.0 million, compared to $54.7 million for the same period in the prior year.
  • Manufacturing and royalty revenues from AMPYRA/FAMPYRA were $29.2 million, compared to $28.2 million for the same period in the prior year.
  • Royalty revenue from BYDUREON was $12.3 million, compared to $10.5 million for the same period in the prior year.